BRCA2-associated breast tumours are usually high-grade, oestrogen-receptor positive, and HER2-negative.5, 6BRCA1 mutation carriers have been reported to have enhanced sensitivity to neoadjuvant chemotherapy with cytotoxic drugs.7 Here, BRCA2 is linked to breast neoplasm.